摘要
目的对缬沙坦+苯磺酸氨氯地平在原发性高血压中的治疗效果进行研讨。方法此次研究所纳入的原发性高血压患者均自2018年10月至2019年10月收治,抽选量为60例,抽选对象均通过研究纳入、排除标准。之中30例组成参照组,施予缬沙坦治疗;余下30例组成观察组,施予缬沙坦联合苯磺酸氨氯地平治疗。经医治和评测剖析,比对两组患者的临床情况。结果观察组的治疗总有效率较参照组有更高占比,数据差异有统计学意义(P<0.05)。观察组的血压水平变化优于参照组,数据差异有统计学意义(P<0.05)。在不良反应率方面,两组患者数据相当,差异细微,无统计学意义(P>0.05)。结论对原发性高血压患者实施缬沙坦联合苯磺酸氨氯地平治疗,可改善患者血压水平,提高治疗效果,且安全性高。
Objective The therapeutic effect of valsartan and amlodipine besylate on essential hypertension was studied.Methods From October 2018 to October 2019,60 patients with essential hypertension were enrolled in the study,and all the subjects were selected according to the inclusion and exclusion criteria of the study.Among them,30 cases were treated with valsartan and the other 30 cases were treated with valsartan and amlodipine besylate.After treatment and evaluation,the clinical conditions of the two groups were compared.Results The total effective rate of the observation group was higher than that of the reference group(P<0.05).The change of blood pressure in the observation group was better than that in the reference group,and the difference was statistically significant(P<0.05).In terms of adverse reaction rate,the data of the two groups were similar,the difference was not statistically significant(P>0.05).Conclusion The combination of valsartan and amlodipine besylate can improve the blood pressure level,improve the therapeutic effect and have high safety.
作者
刘永春
LIU Yong-chun(Haimen No.2 People’s Hospital,Haimen,Jiangsu 226121)
出处
《智慧健康》
2019年第35期191-192,共2页
Smart Healthcare
